<HashMap><database>biostudies-literature</database><scores/><additional><submitter>James BN</submitter><funding>National Institute of Allergy and Infectious Diseases</funding><funding>Intramural NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>National Cancer Institute</funding><funding>NCI NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>e22799</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9990076</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>37(3)</volume><pubmed_abstract>Genome-wide association studies have linked the ORM (yeast)-like protein isoform 3 (ORMDL3) to asthma severity. Although ORMDL3 is a member of a family that negatively regulates serine palmitoyltransferase (SPT) and thus biosynthesis of sphingolipids, it is still unclear whether ORMDL3 and altered sphingolipid synthesis are causally related to non-Th2 severe asthma associated with a predominant neutrophil inflammation and high interleukin-17 (IL-17) levels. Here, we examined the effects of ORMDL3 overexpression in a preclinical mouse model of allergic lung inflammation that is predominantly neutrophilic and recapitulates many of the clinical features of severe human asthma. ORMDL3 overexpression reduced lung and circulating levels of dihydrosphingosine, the product of SPT. However, the mos</pubmed_abstract><journal>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</journal><pubmed_title>Neutrophilia in severe asthma is reduced in Ormdl3 overexpressing mice.</pubmed_title><pmcid>PMC9990076</pmcid><funding_grant_id>R01AI125433</funding_grant_id><funding_grant_id>T32 GM144294</funding_grant_id><funding_grant_id>R01 AI125433</funding_grant_id><funding_grant_id>F31 HL154486</funding_grant_id><funding_grant_id>Z01 DK056014</funding_grant_id><funding_grant_id>P30 CA016059</funding_grant_id><pubmed_authors>Martin RK</pubmed_authors><pubmed_authors>Weigel C</pubmed_authors><pubmed_authors>Proia RL</pubmed_authors><pubmed_authors>Milstien S</pubmed_authors><pubmed_authors>Brown RDR</pubmed_authors><pubmed_authors>Palladino END</pubmed_authors><pubmed_authors>Green CD</pubmed_authors><pubmed_authors>Tharakan A</pubmed_authors><pubmed_authors>Spiegel S</pubmed_authors><pubmed_authors>James BN</pubmed_authors></additional><is_claimable>false</is_claimable><name>Neutrophilia in severe asthma is reduced in Ormdl3 overexpressing mice.</name><description>Genome-wide association studies have linked the ORM (yeast)-like protein isoform 3 (ORMDL3) to asthma severity. Although ORMDL3 is a member of a family that negatively regulates serine palmitoyltransferase (SPT) and thus biosynthesis of sphingolipids, it is still unclear whether ORMDL3 and altered sphingolipid synthesis are causally related to non-Th2 severe asthma associated with a predominant neutrophil inflammation and high interleukin-17 (IL-17) levels. Here, we examined the effects of ORMDL3 overexpression in a preclinical mouse model of allergic lung inflammation that is predominantly neutrophilic and recapitulates many of the clinical features of severe human asthma. ORMDL3 overexpression reduced lung and circulating levels of dihydrosphingosine, the product of SPT. However, the mos</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Mar</publication><modification>2025-04-04T00:35:02.915Z</modification><creation>2025-02-19T01:41:31.084Z</creation></dates><accession>S-EPMC9990076</accession><cross_references><pubmed>36753412</pubmed><doi>10.1096/fj.202201821R</doi></cross_references></HashMap>